[ad_1]
Dallas, March 11, 2024–(BUSINESS WIRE)–Lantern Pharma, Inc. (NASDAQ: LTRN) is an artificial intelligence (“AI”) company using proprietary RADR to develop targeted and innovative cancer treatments.® The AI and machine learning (“ML”) platform with multiple clinical-stage drug programs today presents its fourth quarter and fiscal year 2023 financial results webcast on Monday, March 18 at 4:30 p.m. ET/ It was announced that it would be held at 1:30 p.m. Pacific time.
Management plans to discuss operating and financial results for the fourth quarter and fiscal year ending December 31, 2023, and provide guidance regarding future milestones, clinical trials, and the development of its AI platform RADR.®. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the conference call, and other members of the management team will also participate.
To register for the webinar, please sign up for the Zoom webcast link at the link: Lantern Pharma Q4 2023 Earnings Zoom Webcast Registration Link. A rebroadcast of the earnings call webcast will be available on the Investor Relations section of our website at ir.lanternpharma.com after the earnings call.
About Lantern Pharma
Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and schedule of oncology drug discovery and development. RADR®, our proprietary AI and machine learning (ML) platform, leverages a library of over 60 billion oncology-focused data points and over 200 advanced ML algorithms to improve We help solve billion-dollar, real-world problems. By harnessing the power of AI and leveraging input from our world-class scientific advisors and collaborators, we are advancing research in multiple cancers, including both solid tumors and blood cancers, as well as antibody-drug conjugates (ADCs). We have accelerated the development of a growing pipeline of therapeutics across indications. )program. Our newly developed drug programs are advanced from initial AI insights to first-in-human clinical trials in an average of two to three years and at a cost of approximately $1 million to $2.5 million per program. Ta.
Our flagship development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. Additionally, the Company has established a wholly owned subsidiary, Starlight Therapeutics, to focus on the clinical implementation of the Company’s promising treatments for CNS and brain tumors for which there are no effective treatment options. Our pipeline of innovative, AI-powered product candidates is estimated to have a combined market potential of more than $15 billion annually and will transform lives for hundreds of thousands of cancer patients around the world. may provide a cure.
Additional Information:
Website: www.lanternpharma.com
LinkedIn: https://www.linkedin.com/company/lanternpharma/
X: @lanternpharma
Forward-looking statements:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements regarding: future events or our future financial performance;Potential benefits of our RADR® A platform for identifying drug candidates and patient populations likely to respond to drug candidates. our strategic plans to advance our drug candidate development and antibody-drug conjugate (ADC) development programs; estimates regarding the development timing of our drug candidates and ADC development programs; Expectations and estimates regarding clinical trial timing and patient enrollment.Research and development efforts in internal drug discovery programs and utilization of RADR® A platform to streamline the drug development process. Our mission is to leverage artificial intelligence, machine learning, and biomarker data to streamline and transform the pace, risk, and cost of oncology drug discovery and development and identify patient populations most likely to respond to drug candidates. intention. Estimates regarding patient population, potential market, and potential market size. sales expectations for our drug candidates and our plans to discover and develop drug candidates and maximize their commercial potential by developing such drug candidates ourselves or with others; Any statement that is not a statement of historical fact (“anticipates,” “believes,” “considers,” “may,” “estimates,” “expects,” “intends,” “seeks”) , “may”, “may”, “plan”, “possibility”, “predict”, “project”, “goal”, “model”, “objective”, “objective”, “future statements such as “”, “should”, “will”, “will” or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those expressed in the forward-looking statements.For example, (i) the risk that our research and the research of our collaborators may not be successful; (ii) the risk that none of our product candidates receive FDA marketing approval; and the risk that our products the risk that we may not be able to successfully initiate, conduct or complete clinical trials for our candidates or obtain marketing approval for our product candidates; (iii) the risk that we will not have a drug-based product; our proprietary RADRs;® (iv) the AI Platform has received FDA marketing approval or is incorporated into a commercially available product; and (iv) in our Annual Report on Form 10-K for the year ended December 31, 2022 Other factors listed in the Risk Factors section. Access our Annual Report on Form 10-K for the year ended December 31, 2022 from the SEC Filings for Investors tab on our website at www.lanternpharma.com or from the SEC website can. At www.sec.gov. Given these risks and uncertainties, we believe that our forward-looking statements will prove to be accurate or that other outcomes or events predicted or contemplated by our forward-looking statements will actually occur. We cannot guarantee that this will occur. Do not place undue reliance on these statements. All forward-looking statements in this press release represent the Company’s judgment as of the date of this press release, and unless otherwise required by law, the Company does not believe that any forward-looking statements reflect actual We undertake no obligation to update it to conform to changes in results or our expectations. .
View source version on businesswire.com. https://www.businesswire.com/news/home/20240311884208/ja/
contact address
Investor Information Contact:
Lantern Pharma Investor Information
ir@lanternpharma.com
[ad_2]
Source link
